documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
57 rows where docket_id = "FDA-2007-D-0369" and posted_year = 2021 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, comment_end_date, last_modified, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2007-D-0369-0585 | FDA | None FDA-2007-D-0369 | Draft Guidance on Alprazolam; Revised Guidance; PSG_021726 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:34Z | 1 | 0 | 0900006484e387f6 | ||
| FDA-2007-D-0369-0586 | FDA | None FDA-2007-D-0369 | Draft Guidance on Colesevelam Hydrochloride; Revised Guidance; PSG_021176 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:34Z | 1 | 0 | 0900006484e387f8 | ||
| FDA-2007-D-0369-0572 | FDA | None FDA-2007-D-0369 | Draft Guidance on Leuprolide Acetate; Revised Guidance; PSG_021088 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:32Z | 1 | 0 | 0900006484e387dc | ||
| FDA-2007-D-0369-0613 | FDA | None FDA-2007-D-0369 | Draft Guidance on Lactitol; New Guidance; PSG_211281 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:38Z | 1 | 0 | 0900006484e38839 | ||
| FDA-2007-D-0369-0606 | FDA | None FDA-2007-D-0369 | Draft Guidance on Metoclopramide Hydrochloride; Revised Guidance; PSG_022246 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:37Z | 1 | 0 | 0900006484e3882b | ||
| FDA-2007-D-0369-0603 | FDA | None FDA-2007-D-0369 | Draft Guidance on Desloratadine; Revised Guidance; PSG_021312 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:37Z | 1 | 0 | 0900006484e38825 | ||
| FDA-2007-D-0369-0615 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cenobamate; New Guidance; PSG_212839 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:39Z | 1 | 0 | 0900006484e3883d | ||
| FDA-2007-D-0369-0591 | FDA | None FDA-2007-D-0369 | Draft Guidance on Riluzole; New Guidance; PSG_209080 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:35Z | 1 | 0 | 0900006484e38802 | ||
| FDA-2007-D-0369-0578 | FDA | None FDA-2007-D-0369 | Draft Guidance on Dicyclomine Hydrochloride; New Guidance; PSG_007409-Tab | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:33Z | 1 | 0 | 0900006484e387e8 | ||
| FDA-2007-D-0369-0580 | FDA | None FDA-2007-D-0369 | Draft Guidance on Ondansetron; Revised Guidance; PSG_020781 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:33Z | 1 | 0 | 0900006484e387ec | ||
| FDA-2007-D-0369-0588 | FDA | None FDA-2007-D-0369 | Draft Guidance on Loratadine; Revised Guidance; PSG_020704 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:35Z | 1 | 0 | 0900006484e387fc | ||
| FDA-2007-D-0369-0589 | FDA | None FDA-2007-D-0369 | Draft Guidance on Minocycline Hydrochloride; New Guidance; PSG_209269 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:35Z | 1 | 0 | 0900006484e387fe | ||
| FDA-2007-D-0369-0569 | FDA | None FDA-2007-D-0369 | Draft Guidance on Artesunate; New Guidance; PSG_213036 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:32Z | 1 | 0 | 0900006484e37440 | ||
| FDA-2007-D-0369-0610 | FDA | None FDA-2007-D-0369 | Draft Guidance onColesevelam Hydrochloride; Revised Guidance; PSG_022362 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:38Z | 1 | 0 | 0900006484e38833 | ||
| FDA-2007-D-0369-0608 | FDA | None FDA-2007-D-0369 | Draft Guidance on Minocycline Hydrochloride; New Guidance; PSG_213690 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:38Z | 1 | 0 | 0900006484e3882f | ||
| FDA-2007-D-0369-0614 | FDA | None FDA-2007-D-0369 | Draft Guidance on Pemigatinib; New Guidance; PSG_213736 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:39Z | 1 | 0 | 0900006484e3883b | ||
| FDA-2007-D-0369-0594 | FDA | None FDA-2007-D-0369 | Draft Guidance on Bempedoic Acid; New Guidance; PSG_211616 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:35Z | 1 | 0 | 0900006484e38808 | ||
| FDA-2007-D-0369-0600 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cetirizine Hydrochloride; Revised Guidance; PSG_022578 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:36Z | 1 | 0 | 0900006484e3881f | ||
| FDA-2007-D-0369-0590 | FDA | None FDA-2007-D-0369 | Draft Guidance on Olanzapine; Revised Guidance; PSG_021086 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:35Z | 1 | 0 | 0900006484e38800 | ||
| FDA-2007-D-0369-0597 | FDA | None FDA-2007-D-0369 | Draft Guidance on Tenapanor Hydrochloride; New Guidance; PSG_211801 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:36Z | 1 | 0 | 0900006484e38818 | ||
| FDA-2007-D-0369-0609 | FDA | None FDA-2007-D-0369 | Draft Guidance on Carbidopa; Levodopa; Revised Guidance; PSG_076699 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:38Z | 1 | 0 | 0900006484e38831 | ||
| FDA-2007-D-0369-0593 | FDA | None FDA-2007-D-0369 | Draft Guidance on Lansoprazole; Revised Guidance; PSG_021428 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:35Z | 1 | 0 | 0900006484e38806 | ||
| FDA-2007-D-0369-0612 | FDA | None FDA-2007-D-0369 | Draft Guidance on Opicapone; New Guidance; PSG_212489 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:38Z | 1 | 0 | 0900006484e38837 | ||
| FDA-2007-D-0369-0567 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2022-01-11T04:59:59Z | 2021-12-31T02:00:32Z | 2021-24431 | 0 | 0 | 0900006484e37a93 |
| FDA-2007-D-0369-0575 | FDA | None FDA-2007-D-0369 | Draft Guidance on Leuprolide Acetate; Norethindrone Acetate; Revised Guidance; PSG_203696 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:32Z | 1 | 0 | 0900006484e387e2 | ||
| FDA-2007-D-0369-0568 | FDA | None FDA-2007-D-0369 | Draft Guidance on Beclomethasone Dipropionate Monohydrate; New Guidance; PSG_019389 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:31Z | 1 | 0 | 0900006484e3743e | ||
| FDA-2007-D-0369-0574 | FDA | None FDA-2007-D-0369 | Draft Guidance on Remimazolam Besylate; New Guidance; PSG_212295 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:32Z | 1 | 0 | 0900006484e387e0 | ||
| FDA-2007-D-0369-0582 | FDA | None FDA-2007-D-0369 | Draft Guidance on Sodium Iodide I-131; New Guidance; PSG_016517 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:34Z | 1 | 0 | 0900006484e387f0 | ||
| FDA-2007-D-0369-0587 | FDA | None FDA-2007-D-0369 | Draft Guidance on Tucatinib; New Guidance; PSG_213411 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:34Z | 1 | 0 | 0900006484e387fa | ||
| FDA-2007-D-0369-0571 | FDA | None FDA-2007-D-0369 | Draft Guidance on Triamcinolone Acetonide; Revised Guidance; PSG_012041 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:32Z | 1 | 0 | 0900006484e387da | ||
| FDA-2007-D-0369-0573 | FDA | None FDA-2007-D-0369 | Draft Guidance on Ciclesonide; New Guidance; PSG_022004 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:32Z | 1 | 0 | 0900006484e387de | ||
| FDA-2007-D-0369-0576 | FDA | None FDA-2007-D-0369 | Draft Guidance on Donepezil Hydrochloride; Revised Guidance; PSG_021720 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:33Z | 1 | 0 | 0900006484e387e4 | ||
| FDA-2007-D-0369-0581 | FDA | None FDA-2007-D-0369 | Draft Guidance on Minocycline Hydrochloride; New Guidance; PSG_212379 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:33Z | 1 | 0 | 0900006484e387ee | ||
| FDA-2007-D-0369-0583 | FDA | None FDA-2007-D-0369 | Draft Guidance on Risperidone; Revised Guidance; PSG_021444 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:34Z | 1 | 0 | 0900006484e387f2 | ||
| FDA-2007-D-0369-0595 | FDA | None FDA-2007-D-0369 | Draft Guidance on Glucagon; New Guidance; PSG_212097 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:36Z | 1 | 0 | 0900006484e38814 | ||
| FDA-2007-D-0369-0598 | FDA | None FDA-2007-D-0369 | Draft Guidance on Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic; New Guidance; PSG_212832 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:36Z | 1 | 0 | 0900006484e3881a | ||
| FDA-2007-D-0369-0607 | FDA | None FDA-2007-D-0369 | Draft Guidance on Bempedoic Acid; Ezetimibe; New Guidance; PSG_211617 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:37Z | 1 | 0 | 0900006484e3882d | ||
| FDA-2007-D-0369-0599 | FDA | None FDA-2007-D-0369 | Draft Guidance on Diclofenac Potassium; New Guidance; PSG_020142 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:36Z | 1 | 0 | 0900006484e3881c | ||
| FDA-2007-D-0369-0601 | FDA | None FDA-2007-D-0369 | Draft Guidance on Colesevelam Hydrochloride; New Guidance; PSG_210895 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:37Z | 1 | 0 | 0900006484e38821 | ||
| FDA-2007-D-0369-0602 | FDA | None FDA-2007-D-0369 | Draft Guidance on Clascoterone; New Guidance; PSG_213433 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:37Z | 1 | 0 | 0900006484e38823 | ||
| FDA-2007-D-0369-0577 | FDA | None FDA-2007-D-0369 | Draft Guidance on Mirtazapine; Revised Guidance; PSG_021208 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:33Z | 1 | 0 | 0900006484e387e6 | ||
| FDA-2007-D-0369-0584 | FDA | None FDA-2007-D-0369 | Draft Guidance on Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic; New Guidance; PSG_212121 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:34Z | 1 | 0 | 0900006484e387f4 | ||
| FDA-2007-D-0369-0596 | FDA | None FDA-2007-D-0369 | Draft Guidance on Lemborexant; New Guidance; PSG_212028 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:36Z | 1 | 0 | 0900006484e38816 | ||
| FDA-2007-D-0369-0604 | FDA | None FDA-2007-D-0369 | Draft Guidance on Draft Guidance on Lurbinectedin; New Guidance; PSG_213702 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:37Z | 1 | 0 | 0900006484e38827 | ||
| FDA-2007-D-0369-0605 | FDA | None FDA-2007-D-0369 | Draft Guidance on Rimegepant Sulfate; New Guidance; PSG_212728 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:37Z | 1 | 0 | 0900006484e38829 | ||
| FDA-2007-D-0369-0611 | FDA | None FDA-2007-D-0369 | Draft Guidance on Zolmitriptan; Revised Guidance; PSG_021231 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:38Z | 1 | 0 | 0900006484e38835 | ||
| FDA-2007-D-0369-0592 | FDA | None FDA-2007-D-0369 | Draft Guidance on Rizatriptan Benzoate; Revised Guidance; PSG_020865 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:35Z | 1 | 0 | 0900006484e38804 | ||
| FDA-2007-D-0369-0570 | FDA | None FDA-2007-D-0369 | Draft Guidance on Aripiprazole; Revised Guidance; PSG_021729 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:32Z | 1 | 0 | 0900006484e387d8 | ||
| FDA-2007-D-0369-0579 | FDA | None FDA-2007-D-0369 | Draft Guidance on Methylphenidate; Revised Guidance; PSG_205489 | Other | Guidance | 2021-11-09T05:00:00Z | 2021 | 11 | 2021-11-09T05:00:00Z | 2024-11-07T00:33:33Z | 1 | 0 | 0900006484e387ea | ||
| FDA-2007-D-0369-0561 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances for Ferric Oxyhydroxide; Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2021-09-17T04:00:00Z | 2021 | 9 | 2021-09-17T04:00:00Z | 2021-11-17T04:59:59Z | 2021-11-18T02:00:11Z | 2021-20064 | 0 | 0 | 0900006484d8c141 |
| FDA-2007-D-0369-0560 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2021-08-23T04:00:00Z | 2021 | 8 | 2021-08-23T04:00:00Z | 2021-10-23T03:59:59Z | 2021-10-21T01:00:31Z | 2021-18072 | 0 | 0 | 0900006484c9bafb |
| FDA-2007-D-0369-0558 | FDA | None FDA-2007-D-0369 | Product-Specific Guidance for Olodaterol Hydrochloride; Tiotropium Bromide; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2021-07-28T04:00:00Z | 2021 | 7 | 2021-07-28T04:00:00Z | 2021-09-28T03:59:59Z | 2021-09-25T01:00:52Z | 2021-16046 | 0 | 0 | 0900006484c14747 |
| FDA-2007-D-0369-0554 | FDA | None FDA-2007-D-0369 | Product-Specific Guidance for Cilastatin Sodium; Imipenem; Relebactam; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2021-07-19T04:00:00Z | 2021 | 7 | 2021-07-19T04:00:00Z | 2021-09-18T03:59:59Z | 2021-08-05T20:00:36Z | 2021-15170 | 0 | 0 | 0900006484c01943 |
| FDA-2007-D-0369-0555 | FDA | None FDA-2007-D-0369 | Draft Guidance on Cilastatin Sodium; Imipenem; Relebactam July 2021 | Other | Guidance | 2021-07-19T04:00:00Z | 2021 | 7 | 2021-07-19T04:00:00Z | 2021-07-30T18:56:04Z | 0 | 0 | 0900006484c01d82 | ||
| FDA-2007-D-0369-0550 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2021-05-20T04:00:00Z | 2021 | 5 | 2021-05-20T04:00:00Z | 2021-07-20T03:59:59Z | 2021-08-11T01:00:51Z | 2021-10589 | 0 | 0 | 0900006484b23761 |
| FDA-2007-D-0369-0548 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2021-03-29T04:00:00Z | 2021 | 3 | 2021-03-29T04:00:00Z | 2021-05-25T03:59:59Z | 2021-03-29T12:28:38Z | 2021–06202 | 0 | 0 | 0900006484a84f91 |
| FDA-2007-D-0369-0547 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2021-03-25T04:00:00Z | 2021 | 3 | 2021-03-25T04:00:00Z | 2021-05-25T03:59:59Z | 2021-05-25T01:00:43Z | 2021-06202 | 0 | 0 | 0900006484a7a413 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;